Polycystic Ovary Syndrome
Conditions
Interventions
Control group(Drospirenone and Ethinylestradiol Tablets II ):Oral short-acting contraceptive 3 cycles, oral empty capsule excipient 1 course of treatment
Experimental group (Facel Microbiota transplantation +Drospirenone and Ethinylestradiol Tablets II ):Oral intestinal bacteria capsule 1 course, while oral Drospirenone and Ethinylestradiol Tablets II
Sponsors
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: (1) Polycystic ovary syndrome was confirmed. (2) Age 18-45 years old. (3) No pregnancy plans in the following three months. (4) Abnormal glucose and lipid metabolism. (5) Patients voluntarily participate, sign informed consent, and adhere to treatment follow-up
Exclusion criteria
Exclusion criteria: (1) Severely immunosuppressed patients (neutrophils < 1 500 /mm3, lymphocytes < 500 /mm3). (2) Severe damage of intestinal mucosa. (3) Failure to identify the cause of intestinal mucosal injury. (4) Those currently diagnosed with fulminant colitis or toxic megacolon. (5) Enteral nutrition patients who cannot tolerate 50% of heat calorie requirements due to severe diarrhea, significant fibrous intestinal stenosis, severe gastrointestinal bleeding, high-flow intestinal fistula and other reasons. (6) Patients with severe systemic infection who meet the diagnostic criteria for systemic inflammatory response syndrome. (7) Patients with parenteral organ infection requiring broad-spectrum antibiotic intervention. (8) Patients with severe malnutrition (body mass index < 15 kg/m2) and severe hypoproteinemia (albumin < 25 g/L). (9) Patients with congenital or acquired immunodeficiency. (10) Those who have recently been treated with high-risk immunosuppressive/cytotoxic products, such as rituximab, doxorubicin, or medium-high dose steroid hormones (20 mg/ day or higher) for more than 4 weeks. (11) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Waistline;Body composition analysis;Liver function;Renal function;Total cholesterol;Triglyceride;Low density lipoprotein;High-density lipoprotein;Fasting blood-glucose;Fasting insulin;Fecal genetic testing; | — |
Secondary
| Measure | Time frame |
|---|---|
| Height;Weight;Body Mass Index(BMI);Blood Pressure;Heart rate;Hip cricumference;Blood routine examination;Human Chorionic Gonadotropin, HCG; | — |
Countries
China
Contacts
Public ContactXiangyan Ruan
Beijing Obstetrics and Gynecology Hospital, Capital Medical University
Outcome results
None listed